HOME >> MEDICINE >> NEWS
Inflammation elevates risk of cardiac death in rheumatoid arthritis patients

ROCHESTER, Minn. -- Mayo Clinic epidemiologists have found that the systemic inflammation characterizing rheumatoid arthritis may be to blame for the increased risk of cardiovascular death in patients with the disease.

"We believe that inflammation is a strong risk factor for cardiovascular disease among rheumatoid arthritis patients," says Hilal Maradit Kremers, M.D., lead study investigator and research associate in the Mayo Clinic Department of Health Sciences Research.

Rheumatoid arthritis patients have a significantly increased risk of dying of a heart condition if they have swelling in the large joints, rheumatoid vasculitis (inflammation of the blood vessels), rheumatoid lung disease or a high erythrocyte sedimentation rate (a blood test commonly known as ESR that measures level of inflammation in the body), report the investigators in the March issue of Arthritis & Rheumatism (http://www.rheumatology.org/publications/ar).

"Our previous research showed that rheumatoid arthritis patients have a higher risk of early death than others and that these deaths are mostly due to cardiovascular disease," says Sherine Gabriel, M.D., the study's senior author and Mayo Clinic rheumatologist, epidemiologist and chair of the Department of Health Sciences Research. "We suspect that systemic inflammation promotes this risk. Our findings support this hypothesis."

The exact means by which the inflammation in rheumatoid arthritis can lead to heart disease is unclear, say the Mayo Clinic investigators, who indicate this is currently under study. The investigators hypothesize that if the degree of a rheumatoid arthritis patient's inflammation can be closely monitored and kept under strict control, the risk of death by heart condition may decrease. This hypothesis is also the subject of ongoing research.

The study was conducted using the resources of the Rochester Epidemiology Proje
'"/>

Contact: Lisa Lucier
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Mar-2005


Page: 1 2

Related medicine news :

1. Inflammation of placental membranes may be risk factor for cerebral palsy
2. Inflammation may increase stroke risk in men with hypertension
3. Inflammation reduced after just two weeks on statin drug
4. Study Suggests Inflammation Signs Can Show Who Will Develop Diabetes
5. Antibiotics Reduce Inflammation In Heart Disease But Effect On Heart Attacks Remains Unproven
6. Scientists Discover How Aspirin Reduces Inflammation
7. Study Ties Cerebral Palsy To Inflammation And Blood-Clotting Abnormalities
8. Snipping Inflammation In The Bud; New Agents May Provide Relief
9. Anemia elevates risk of physical decline in older people
10. Coffee drinking elevates plasma homocysteine and risk factors for coronary heart disease
11. High cholesterol elevates womens risk of stroke death

Post Your Comments:
(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: